Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: A novel molecular target for endometriosis therapy

Biology of Reproduction

Volumn 83, Issue 5, 2010, Pages 866-873

  Novella Maestre, Edurne ^a   Carda, Carmen ^b   Ruiz Sauri, Amparo ^b   Garcia Velasco, Juan A ^c   Simon, Carlos ^c   Pellicer, Antonio ^a,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Angiogenesis; Cabergoline; Dopamine; Dopamine agonist; Dopamine receptor 2; Endometriosis; Endometrium; KDR; VEGF

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANIMALS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIOSIS; ENDOMETRIUM; ERGOLINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OOCYTE DONATION; RECEPTORS, DOPAMINE D2; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS; YOUNG ADULT;

MUS MUSCULUS;

EID: 77958546519     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.110.084392     Document Type: Article

References (41)

1. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update 2009; 15:441-461.
2. Kyama CM, Mihalyi A, Simsa P, Mwenda JM, Tomassetti C, Meuleman C, D'Hooghe TM. Non-steroidal targets in the diagnosis and treatment of endometriosis. Curr Med Chem 2008; 15:1006-1017.
3. Ozkan S, Arici A. Advances in treatment options of endometriosis. Gynecol Obstet Invest 2009; 67:81-91.
4. Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs 2009; 69:649-675.
5. Delvoux B, Groothuis P, D'Hooghe T, Kyama C, Dunselman G, Romano A. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab 2009; 94:876-883.
6. Maas JW, Groothuis PG, Dunselman GA, de Goeij AF, Struijker-Boudier HA, Evers JL. Endometrial angiogenesis throughout the human menstrual cycle. Hum Reprod 2001; 16:1557-1561.
7. Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993; 59:681-684.
8. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007; 13:331-342.
9. Hull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, Fan TP, Smith SK. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003; 88:2889-2899.
10. Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thijssen VL, Evers JL, Groothuis PG. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004; 89:1089-1095.
11. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, Smith SK. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996; 98:482-489. (Pubitemid 26255749)
12. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB, Taylor RN. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996; 81:3112-3118.
13. Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril 2000; 73:166-170.
14. Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 2006; 132:501-519.
15. Eljarmak D, Lis M, Cantin M, Carriere PD, Collu R. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma. Horm Res 1985; 21:160-167.
16. Basu S, Dasgupta PS. Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci 1997; 42:1260-1264.
17. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 2004; 64:5551-5555.
18. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001; 7:569-574. (Pubitemid 32448324)
19. Novella-Maestre E, Carda C, Noguera I, Ruiz-Saurí A, Garcia-Velasco JA, Simon C, Pellicer A. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009; 24:1025-1035.
20. Arai F, Kishimoto Y, Tada K, Kondo Y, Kudo T. The presence and role of the dopamine DA-2 receptor in the human decidua. J Obstet Gynaecol Res 2000; 26:449-454.
21. Reese J, Binart N, Brown N, Ma WG, Paria BC, Das SK, Kelly PA, Dey SK. Implantation and decidualization defects in prolactin receptor (PRLR)-deficient mice are mediated by ovarian but not uterine PRLR. Endocrinology 2000; 141:1872-1881.
22. Gregoriou G, Bakas P, Vitoratos N, Papadias K, Goumas K, Chryssicopoulos A, Creatsas G. Evaluation of serum prolactin levels in patients with endometriosis and infertility. Gynecol Obstet Invest 1999; 48:48-51.
23. Cunha-Filho JS, Gross JL, Lemos NA, Dias EC, Vettori D, Souza CA, Passos EP. Prolactin and growth hormone secretion alter thyrotrophin-releasing hormona infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis. Hum Reprod 2002; 17:960-965.
24. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1:3-25.
25. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, Simon C, Pellicer A. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006; 147:5400-5411.
26. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J, D'Amato RJ, Rupnick MA. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005; 83:171-181.
27. Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J, D'Amato RJ. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 2006; 85:71-77.
28. Álvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simon C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92:2931-2937.
29. Tanji H, Araki T, Nagasawa H, Itoyama Y. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. Brain Res 1999; 824:224-231.
30. Jiang M, Spicher K, Boulay G, Wang Y, Birnbaumer L. Most central nervous system D2 dopamine receptors are coupled to their effectors by Go. Proc Natl Acad Sci U S A 2001; 98:3577-3582.
31. Rydén L, Linderholm B, Nielsen NH, Emdin S, Jönsson PE, Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003; 82:147-154.
32. American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817-821.
33. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6:45-55.
34. Tseng L, Mazella J, Goligorsky MS, Rialas CM, Stefano GB. Dopamine and morphine stimulate nitric oxide release in human endometrial glandular epithelial cells. J Soc Gynecol Invest 2000; 7:343-347.
35. Minagawa M, Narita J, Tada T, Maruyama S, Shimizu T, Bannai M, Oya H, Hatakeyama K, Abo T. Mechanisms underlying immunologic states during pregnancy: possible association of the sympathetic nervous system. Cell Immunol 1999; 196:1-13.
36. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor in endometriosis. Hum Reprod 1998; 13:1686-1690.
37. Machado DE, Abrao MS, Berardo PT, Takiya CM, Nasciutti LE. Vascular density and distribution of endothelial growth factor (VEGF) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008; 90:148-155.
38. Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ, Becu-Villalobos D. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 2005; 146:2952-2962.
39. Cristina C, Garcia-Tornadu I, Diaz-Torga G, Rubinstein M, Low MJ, Becu-Villalobos D. Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 2006; 35:50-63.
40. Rey-Ares V, Lazarov N, Berg D, Berg U, Kunz L, Mayerhofer A. Dopamine receptor repertoire of human granulosa cells. Reprod Biol Endocrinol 2007; 5:40-50.
41. D'Hooghe TM, Kyama CK, Mihalyi AM, Chai D, Falconer H, Mwenda JM. The baboon model for translational research in endometriosis. Reprod Sci 2009; 16:152-161.